Daré Bioscience (NASDAQ:DARE) Stock Price Passes Below Two Hundred Day Moving Average of $0.39

Daré Bioscience, Inc. (NASDAQ:DARE)’s share price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.39 and traded as low as $0.28. Daré Bioscience shares last traded at $0.29, with a volume of 415,941 shares changing hands.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the company. Dawson James lowered Daré Bioscience from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 30th. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Daré Bioscience in a report on Monday, April 1st. Finally, Brookline Capital Management cut Daré Bioscience from a “buy” rating to a “hold” rating in a research report on Wednesday, April 17th.

Daré Bioscience Price Performance

The company has a market capitalization of $28.77 million, a P/E ratio of -0.84 and a beta of 1.16. The stock’s fifty day simple moving average is $0.46 and its 200-day simple moving average is $0.39.

Daré Bioscience (NASDAQ:DARE) last posted its quarterly earnings data on Thursday, March 28th. The biotechnology company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.06. The business had revenue of $1.81 million during the quarter, compared to the consensus estimate of $2.17 million. On average, research analysts predict that Daré Bioscience, Inc. will post -0.22 earnings per share for the current year.

Institutional Investors Weigh In On Daré Bioscience

A hedge fund recently bought a new stake in Daré Bioscience stock. Armistice Capital LLC acquired a new position in Daré Bioscience, Inc. (NASDAQ:DARE) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 6,470,000 shares of the biotechnology company’s stock, valued at approximately $2,988,000. Armistice Capital LLC owned 7.37% of Daré Bioscience at the end of the most recent quarter. Institutional investors own 6.70% of the company’s stock.

About Daré Bioscience

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.